UPDATE: March, 2026 Two new Phase 3 clinical trials to study the efficacy of baricitinib as a disease-modifying therapy for T1D. Baricitinib is a JAK inhibitor that interferes with signaling pathways critical to both immune cells and beta cells. This drug has the potential to extend the “honeymoon period” of T1D, meaning that it could preserve remaining […]
On Jan 7, 2025 (Sweden), Sana Biotechnology released significant clinical data: the first person with type 1 diabetes (T1D) who received deceased donor islets engineered to evade the immune system is producing insulin without immunosuppression. UPDATE: March, 2026 At the Advanced Technologies & Treatment for Diabetes international conference held in Barcelona, Spain Per-Ola Carlsson, M.D., Ph.D., presented […]
From left to right: Breakthrough T1D Canada staff members Lara Green and Lauren Germain, along with Justice Maki-Chambers and Roslynn Baird, Client Services Administrator, and Godrihwasido (Cayuga “Overseer”), Executive Director of IDHC respectively. Breakthrough T1D Canada is partnering through a community grant to the Indigenous Diabetes Health Circle (IDHC) to help to address an unmet […]
Danica Doble, a fitness coach and content creator who has been living with type 1 diabetes (T1D) since 2009 recently partnered with Breakthrough T1D Canada as a social media ambassador. She sat down with the organization to share more about her journey, and why she’s so open about how teenage struggles living with T1D empowered […]
Sunday, March 8 is International Women’s Day (IWD), celebrated globally and this year recognizing its 115 anniversary. On IWD we are asked to imagine a world that is truly equal. For that to happen, we need a world free of bias, stereotypes, and discrimination. A world that’s diverse, equitable, and inclusive. A world where difference is not only recognized but also valued and celebrated. The theme for IWD 2026 is ‘Give To Gain’. Because, when we […]
Breakthrough T1D Canada is excited to continue its successful partnership with the Canadian Islet Research and Training Network (CIRTN) and announce a fourth cohort of co-funded trainees beginning in 2026. CIRTN was established in 2020 as a world-class training and research network with joint contributions from the University of Alberta, University of British Columbia, University of Manitoba, […]
Stephanie Atkinson, a Montreal, QC based adult Breakthrough T1D Canada ambassador, sat down with the organization to discuss what drew her to volunteering and what it’s like to be diagnosed as a busy mother and businesswoman. Tell us a little bit more about yourself My name is Stephanie Atkinson. I’m a mom of four, a […]
What does a cure for type 1 diabetes (T1D) look like? Authors: Katie Bartel, Beth Miller, Tony Lucas, Benjamin Mammon, for The Breakthrough T1D Canucks For Kids Fund Centre of Excellence at UBC T1D Lived Advisory Group That was the question that the Type 1 Diabetes Lived Experience Advisory Group attempted to answer through a […]
Do you prefer the sweetness of a Hershey’s kiss, or maybe you like the spice of a cinnamon heart? For most of us, we can grab a handful of Valentine’s Day candy without thinking about it. But for people living with type 1 diabetes (T1D) every snack, every meal, every piece of food eaten must […]
On January 20, 2026 Novo Nordisk (“Novo”) and Vancouver-based Aspect Biosystems (“Aspect”), announced a new phase of their partnership focused on developing curative cell therapies for type 1 diabetes (T1D). Since 2023, Aspect and Novo have worked together on technologies aimed at producing insulin-secreting islet cells from stem cells. Under the revised partnership, Aspect has acquired […]
Ramya (left), Dr. Bruce Verchere, Co-Director at the Centre (middle), and Dr. Benjamin Mammon, another member of the T1D Lived Experience Advisory Group (right). Photo credit: Macy Yap Type 1 diabetes stories help shape research Ramya Hosak was diagnosed with type 1 diabetes (T1D) at age 19 while attending university. Since then, she has been a devoted volunteer, helping others navigate the challenges of T1D and the steep learning curve that accompanies a life-altering diagnosis. As co-chair of the T1D Lived Experience […]
On January 6th, 2026, Encellin (California, Quebec) reported positive interim results of its Phase 1 clinical trial of encapsulated islets in people with type 1 diabetes (T1D), which is being carried out in Toronto and Montreal. Trial Details:In Encellin’s trial, cadaveric human donor islets are being encapsulated in Encellin’s Encapsulated Cell Replacement Therapy (ENCRT) device and […]
